Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board

Written by 2020HCP.com. Posted in News

BEDFORD Mass., October 21, 2019 — Verseau Therapeutics, Inc. (“Verseau”) launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. In addition, George Golumbeski, Ph.D., a champion of innovation and former Executive Vice President of Celgene, has been appointed Chairman of the Verseau Board of Directors. Verseau is developing novel, first-in-class immunotherapies that target modulation of macrophages, the master orchestrators of the immune system. The proceeds from the financing will support advancement of Verseau’s macrophage checkpoint modulator (MCM) programs to the clinic. Link to Full Article